Double maintains 1 strategies that include SRRK - Scholar Rock Holding Corp.
Current Value
$35.801 Year Return
Current Value
$35.801 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTG | <0.01% | $4.66B | +30.74% | 3.40% |
PLTK | <0.01% | $1.78B | -39.77% | 8.49% |
ACEL | -<0.01% | $1.01B | +15.98% | 0.00% |
AGL | 0.01% | $956.23M | -64.68% | 0.00% |
FMC | -0.01% | $5.36B | -25.44% | 5.50% |
CM | -0.01% | $65.09B | +46.57% | 4.85% |
LPLA | 0.02% | $29.19B | +30.67% | 0.33% |
CSAN | -0.03% | $2.29B | -49.59% | 0.00% |
MOGO | -0.03% | $30.10M | -16.33% | 0.00% |
EVRI | 0.03% | $1.24B | +69.40% | 0.00% |
SMPL | -0.03% | $3.22B | -11.68% | 0.00% |
XYZ | -0.03% | $40.98B | +3.32% | 0.00% |
PINC | -0.03% | $1.78B | +15.75% | 3.86% |
MLNK | -0.03% | $1.25B | -23.92% | 0.00% |
TNL | 0.04% | $3.45B | +15.36% | 4.08% |
VAC | 0.04% | $2.55B | -15.45% | 4.23% |
QTRX | -0.04% | $258.39M | -49.66% | 0.00% |
HLMN | 0.04% | $1.41B | -19.32% | 0.00% |
CWCO | -0.04% | $474.80M | +12.40% | 1.42% |
ARI | -0.05% | $1.36B | +0.20% | 11.46% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TPMN | -16.83% | $30.77M | 0.65% |
LMBS | -16.41% | $5.11B | 0.64% |
IAK | -14.06% | $807.50M | 0.39% |
BTAL | -12.57% | $296.79M | 1.43% |
CGSD | -12.04% | $1.33B | 0.25% |
KIE | -11.89% | $835.00M | 0.35% |
GBIL | -10.89% | $6.40B | 0.12% |
ICSH | -10.67% | $6.02B | 0.08% |
BILS | -10.65% | $3.86B | 0.1356% |
SHV | -10.52% | $20.67B | 0.15% |
CARY | -10.47% | $347.36M | 0.8% |
TBLL | -9.89% | $2.14B | 0.08% |
XLU | -9.68% | $18.86B | 0.09% |
GSY | -9.61% | $2.73B | 0.22% |
FIXD | -9.58% | $3.42B | 0.65% |
KMLM | -9.57% | $186.80M | 0.9% |
VGSH | -9.52% | $22.80B | 0.03% |
FPEI | -9.43% | $1.60B | 0.85% |
VPU | -9.36% | $6.99B | 0.09% |
EPI | -9.31% | $3.38B | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBHG | <0.01% | $315.48M | 0.35% |
GHYB | 0.01% | $90.38M | 0.15% |
PREF | -0.01% | $1.22B | 0.55% |
EFAV | -0.02% | $5.40B | 0.2% |
SPHQ | -0.02% | $13.80B | 0.15% |
SHLD | 0.04% | $2.76B | 0.5% |
EWJ | -0.04% | $14.81B | 0.5% |
TAXF | -0.04% | $488.44M | 0.29% |
FPE | 0.04% | $5.91B | 0.85% |
LTPZ | -0.04% | $672.84M | 0.2% |
HYGV | 0.05% | $1.23B | 0.37% |
FXH | -0.05% | $898.02M | 0.62% |
IFV | -0.06% | $130.30M | 1.09% |
BBJP | 0.06% | $13.07B | 0.19% |
SPSK | -0.07% | $316.15M | 0.5% |
XRT | -0.07% | $260.52M | 0.35% |
DMXF | -0.08% | $808.08M | 0.12% |
VWOB | 0.08% | $5.19B | 0.15% |
EMB | 0.08% | $13.58B | 0.39% |
XLF | 0.08% | $49.25B | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UVE | -48.78% | $776.51M | +47.92% | 2.31% |
HCI | -42.01% | $1.74B | +63.93% | 1.06% |
ACIC | -31.12% | $516.90M | +5.24% | 0.00% |
HRTG | -29.50% | $726.17M | +230.93% | 0.00% |
RNR | -29.43% | $11.75B | +8.03% | 0.66% |
EG | -28.28% | $14.32B | -11.61% | 2.37% |
FIHL | -22.91% | $1.78B | -0.25% | 1.84% |
CB | -21.24% | $114.25B | +11.78% | 1.31% |
ACGL | -20.21% | $33.85B | -5.85% | 0.00% |
IMRN | -20.20% | $10.82M | -23.55% | 0.00% |
RLI | -20.15% | $6.55B | +3.69% | 1.25% |
CON | -20.03% | $2.71B | -10.00% | 0.59% |
AIZ | -18.62% | $9.98B | +18.40% | 1.59% |
DUK | -18.19% | $90.88B | +16.65% | 3.59% |
ALL | -17.60% | $51.84B | +22.61% | 1.95% |
AWK | -17.16% | $26.90B | +6.78% | 2.27% |
PLMR | -16.60% | $4.10B | +89.01% | 0.00% |
HG | -16.45% | $2.20B | +28.77% | 0.00% |
PGR | -15.35% | $154.76B | +27.10% | 1.86% |
IAG | -14.96% | $4.07B | +88.80% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CNYA | 29.16% | $206.04M | 0.6% |
ASHR | 26.58% | $1.91B | 0.65% |
LIT | 23.96% | $824.14M | 0.75% |
REMX | 23.05% | $290.89M | 0.58% |
GXC | 20.05% | $431.44M | 0.59% |
CQQQ | 19.05% | $1.04B | 0.65% |
KBA | 18.70% | $176.19M | 0.56% |
FLCH | 17.66% | $200.01M | 0.19% |
MCHI | 16.98% | $6.44B | 0.59% |
CXSE | 16.89% | $423.19M | 0.32% |
EWX | 16.55% | $697.31M | 0.65% |
USL | 16.05% | $42.26M | 0.85% |
BATT | 15.15% | $61.84M | 0.59% |
CHIQ | 14.90% | $234.78M | 0.65% |
DBE | 14.34% | $51.16M | 0.77% |
OILK | 14.19% | $71.89M | 0.69% |
BNO | 14.07% | $103.68M | 1% |
DBO | 14.03% | $224.00M | 0.77% |
JPEM | 13.59% | $336.06M | 0.44% |
UGA | 13.24% | $72.51M | 0.97% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OCFT | 45.17% | $264.91M | +355.70% | 0.00% |
APD | 37.80% | $62.84B | +9.42% | 2.53% |
EH | 31.40% | $889.66M | +25.11% | 0.00% |
AVNW | 30.74% | $304.88M | -16.56% | 0.00% |
GNRC | 26.98% | $8.41B | +7.71% | 0.00% |
NIU | 25.00% | $236.96M | +95.40% | 0.00% |
STG | 22.00% | $29.06M | -28.79% | 0.00% |
PLL | 21.92% | $128.17M | -41.48% | 0.00% |
OC | 21.89% | $11.74B | -20.55% | 1.87% |
LQDA | 21.49% | $1.12B | +9.17% | 0.00% |
CRNC | 21.42% | $408.36M | +233.57% | 0.00% |
BHVN | 21.34% | $1.44B | -59.41% | 0.00% |
NECB | 19.65% | $327.31M | +31.79% | 2.56% |
LSTR | 18.33% | $4.87B | -23.51% | 1.06% |
SMCI | 18.06% | $28.40B | -41.93% | 0.00% |
NOAH | 18.00% | $804.75M | +38.91% | 8.90% |
CSIQ | 17.69% | $758.80M | -23.19% | 0.00% |
CPNG | 17.21% | $55.94B | +47.06% | 0.00% |
JKS | 17.01% | $1.08B | +4.44% | 0.00% |
CPSH | 16.59% | $40.67M | +64.71% | 0.00% |
Finnhub
Scholar Rock Holding Corporation dropped from Russell 3000E Growth Index...
Finnhub
Scholar Rock Holding Corporation dropped from Russell Microcap Index...
Finnhub
Scholar Rock Holding Corporation dropped from Russell Microcap Value Index...
Yahoo
CAMBRIDGE, Mass., June 23, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California.
SeekingAlpha
Scholar Rock: EMBRAZE Results Drive The Stock Higher
Yahoo
(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.